Previously, we reported that Akt inactivation determines the sensitivity of hepatocellular carcinoma (HCC) cells to bortezomib. In this study, we report that cancerous inhibitor of protein phosphatase 2A (CIP2A), a cellular inhibitor of protein phosphatase 2A (PP2A), mediates the apoptotic effect of bortezomib in HCC. Silencing PP2A by small interference RNA (siRNA) abolishes bortezomibinduced down-regulation of phospho-Akt and apoptosis. Bortezomib increases PP2A activity in sensitive HCC cells, including Sk-Hep1, Hep3B and Huh-7, but not in resistant PLC5 cells. Bortezomib down-regulates CIP2A in a dose-and time-dependent manner in all sensitive HCC cells, whereas no alterations in CIP2A were found in resistant PLC5 cells. Knockdown of CIP2A by siRNA restored bortezomib's effects on apoptosis and PP2A activity in PLC5 cells. Moreover, over-expression of CIP2A up-regulated phospho-Akt and protected Sk-Hep1 cells from bortezomib-induced apoptosis. It is significant that, ectopic expression of CIP2A decreased Akt-related PP2A activity, whereas silencing CIP2A increased this activity, indicating that CIP2A negatively regulates Akt-related PP2A activity in HCC cells, furthermore, our in vivo data showed that bortezomib down-regulates CIP2A and up-regulates PP2A activity in Huh-7 tumors, but not in PLC5 tumors. In conclusion, inhibition of CIP2A determines the effects of bortezomib on apoptosis and PP2A-dependent Akt inactivation in HCC.
Introduction
Hepatocellular carcinoma (HCC), the fifth most common solid tumor worldwide (Verslype et al., 2009) , remains one of the most difficult tumors to be treated. For patients with early HCC, surgery, local destructive therapies and liver transplantation provide curative potential (Verslype et al., 2009) . However, HCC is often diagnosed at an advanced stage, and many patients with advanced stage are not eligible for the curative therapies. Moreover, traditional systemic chemotherapy shows low efficacy and no proven survival benefits (Verslype et al., 2009) . Recently, a multikinase inhibitor, sorafenib, has shown survival benefit in patients with advanced HCC and preserved liver function, highlighting a promising molecular targeted strategy for advanced HCC (Llovet et al., 2008) .
Bortezomib, a modified dipeptidyl boronic acid, is a specifically designed reverse-inhibitor of the 26S proteasome-a key barrel-shaped multiprotein for degradation of ubiquitylated proteins. It is well known that the transcription factor nuclear factor-kB has a vital role in cell proliferation, apoptosis, tumor cell invasiveness and metastasis, tumorigenesis and angiogenesis, particularly in multiple myeloma (Orlowski and Baldwin, 2002; Voorhees and Orlowski, 2006; Orlowski and Kuhn, 2008) . Through a blockade on the proteasome degradation of IkB, an inhibitor of nuclear factor-kB, bortezomib has shown remarkable in-vitro and clinical antitumor activity against multiple myeloma and mantel-cell lymphoma that has rendered its approval in clinical treatment for these two hematological malignancies (Voorhees and Orlowski, 2006; Orlowski and Kuhn, 2008) . In contrast, bortezomib has shown less promising efficacy for the treatment of solid tumors in several clinical trials (Davis et al., 2004; Voorhees and Orlowski, 2006; Ocio et al., 2008) , suggesting that bortezomib selectively kills certain cancer cells and that the anti-tumor mechanism of bortezomib in solid tumors may differ from that in hematological malignancies. Indeed, our previous study (Chen et al., 2008) showed that down-regulation of P-Akt is a major determinant of bortezomib sensitivity in HCC cells, and that bortezomib-induced apoptosis is not associated with proteasome inhibition in HCC cells. The down-regulation of P-Akt by bortezomib could be either through decrease of upstream kinase signaling (such as PDK1 and PI3K) or through increase of phosphatase activity. Further investigation of the mechanism by which bortezomib reduces P-Akt, showed that protein phosphatase 2A (PP2A) may have a major role in regulating the bortezomib-induced downregulation of P-Akt and subsequent apoptosis in HCC cells (Chen et al., 2009a) . Our data illustrated that okadaic acid, a PP2A inhibitor, reversed the down-regulation of P-Akt in bortezomib-treated cells, and PP2A knockdown by small interference RNA (siRNA) also reduced apoptosis induced by the combination of TRAIL and bortezomib, indicating that bortezomib-induced P-Akt down-regulation may be PP2A dependent (Chen et al., 2009a) .
PP2A is a complex of serine/threonine protein phosphatase that regulates cell proliferation by dephosphorylation of oncogenic kinases, such as Akt and ERK (Bielinski and Mumby, 2007) . PP2A is composed of a scaffolding A subunit and a catalytic C subunit (the AC core enzyme), and a wide variety of regulatory B subunits (Janssens and Goris, 2001 ). The substrate specificity, cellular localization and enzymatic activity of PP2A are believed to be largely regulated by the regulatory B subunit (Mumby, 2007) . Several cellular inhibitors of PP2A, including SET (Neviani et al., 2005) and cancerous inhibitor of protein phosphatase 2A (CIP2A) (Junttila et al., 2007) , have recently been identified. CIP2A, originally named KIAA1524 or P90, has been cloned from patients with HCC (Soo Hoo et al., 2002) . CIP2A has been shown to promote anchorage-independent cell growth and in vivo tumor formation by inhibiting PP2A activity toward c-Myc (Junttila et al., 2007) . In addition to HCC, CIP2A is over-expressed in several human malignancies, including gastric cancer, head and neck cancer, colon cancer and breast cancer. (Junttila et al., 2007; Li et al., 2008; Come et al., 2009) Similarly, (Come et al., 2009) found that CIP2A is associated with clinical aggressiveness in human breast cancer and promotes the malignant growth of breast cancer cells.
In this study, we confirmed that bortezomibinduced apoptosis in HCC cells is by the up-regulation of PP2A activity and subsequent P-Akt downregulation. Moreover, we demonstrated that CIP2A, through inhibition of PP2A-dependent P-Akt inactivation, mediates the apoptotic effect of bortezomib in HCC cells. Bortezomib down-regulates CIP2A in sensitive HCC cells, but not in resistant ones. Moreover, knockdown of CIP2A by siRNA restores bortezomib's effects on PP2A-dependent P-Akt inactivation in resistant HCC cells. CIP2A may be implicated as a biomarker for predicting clinical response of bortezomib to HCC treatment.
Results
PP2A has a role in mediating the effects of bortezomib on P-Akt and apoptosis To answer the question of how bortezomib downregulates phospho-Akt in HCC cells, we previously examined the expression levels of upstream PI3K signaling proteins, and the mammalian target of complex 2 (mTORC2) and found that bortezomib did not influence expression levels of these proteins (Chen et al., 2008) . Furthermore, we demonstrated that PP2A mediated the sensitizing effect of bortezomib on TRAIL-induced cell apoptosis in HCC (Chen et al., 2009a) . In this study, we investigated whether PP2A has a role in the effects of bortezomib on phospho-Akt (P-Akt) and apoptosis. As shown in Figure 1a , Sk-Hep1 cells were transfected with control or PP2A siRNA for 48 h and were then exposed to DMSO or bortezomib for 24 h. Our data show that knockdown of PP2A decreased the effect of bortezomib-induced apoptosis ( Figure 1a ). It is of note that bortezomib decreased the protein level of Akt in Sk-Hep1 cells modestly. It may be possible due to the influence of massive cell death induced by bortezomib. In addition, bortezomib significantly increased the phosphatase activity of PP2A in bortezomib-sensitive HCC cell lines, including Sk-Hep1, Hep3B and Huh-7, whereas bortezomib did not influence the phosphatase activity in resistant PLC5 cells (Figure 1b) , suggesting that bortezomib might affect P-Akt through up-regulation of PP2A activity as PLC5 cells are resistant to bortezomib-induced apoptosis and Akt inactivation. It is of note that the use of okadaic acid, a PP2A inhibitor as a negative control, decreased the phosphatase activity of PP2A in Sk-Hep1 cells and use of forskolin, a PP2A agonist as a positive control, increased the activity (Figure 1b) . However, bortezomib did not affect the expression of PP2A complex, including subunit A, and C ( Figure 1c ). It is of note that bortezomib decreased PP2A-56g in both sensitive Huh-7 and resistant PLC5 cells, suggesting PP2A-56g may not be the target to determine the sensitivity to bortezomib in HCC. To examine the protein-protein interaction between PP2A and Akt, we performed co-immunoprecipitation analysis. Bortezomib did not alter the dynamic interactions between Akt and PP2A, suggesting that bortezomib may not direct PP2A to Akt in HCC cells (Figure 1d ).
Inhibition of CIP2A determines the effects of bortezomib on P-Akt and apoptosis in HCC Our results indicate that bortezomib may mediate apoptosis in HCC cells through the up-regulation of PP2A activity. We identified that inhibition of CIP2A is the major determinant of bortezomib-induced apoptosis in HCC cells. As shown in Figures 2a and b , bortezomib decreased the protein levels of CIP2A and induced apoptosis in all sensitive HCC cells in a dose-dependent manner, but not in resistant PLC5 cells. Furthermore, inhibition of CIP2A is associated with apoptosis induction evidenced by the activation of caspase-9, and poly (ADP-ribose) polymerase cleavage in sensitive Sk-Hep1 cells in a time-dependent manner ( Figure 2c ). Conversely, bortezomib did not affect protein levels of CIP2A, P-Akt and apoptosis induction, as well in PLC5 cells (Figure 2d ). These results suggest that the inhibition of CIP2A determines bortezomib-induced apoptosis in HCC cells. To examine whether the protein levels of endogenous CIP2A might be associate with the drug sensitivity, we analyzed the expression of CIP2A and other related proteins under the treatment of bortezomib. As shown in Figure 2e , Sk-Hep1 and Huh-7 have higher protein levels of CIP2A than Hep3B and PLC5. However, bortezomib down-regulated CIP2A in sensitive cell lines, including Sk-Hep1, Hep3B and Huh-7, but not in resistant PLC5 cells, suggesting that the expression level of CIP2A does not determine the sensitivity to bortezomib in HCC cells. Moreover, our data showed that bortezomib inhibited Huh-7 tumor growth, whereas PLC5 tumor showed resistance to bortezomib in vivo even though the expression of CIP2A was higher in Huh-7 (Chen et al., 2008 and Figure 2e ), indicating that CIP2A expression does not predict the response to bortezomib in vivo. However, it remains unclear that, why PLC5 cells show resistance to bortezomibinduced CIP2A inhibition. In addition, although the PHdomain leucine-rich repeat phosphatase has been proposed to regulate P-Akt at Ser473 (Gao et al., 2005) , our data showed that bortezomib did not alter the expression of PHdomain leucine-rich repeat phosphatase in four HCC cell lines, indicating that PH-domain leucine-rich repeat phosphatase may not have a role in mediating the drug's effect ( Figure 2e ). In addition to CIP2A, SET has also been shown as an inhibitor of PP2A (Neviani et al., 2005) . Therefore, we examined SET in our HCC cells, and found that the protein levels of SET were not changed significantly in bortezomib-treated cells (Figure 2e ), suggesting that SET dose not mediate the effect of bortezomib in HCC cells.
Target validation of CIP2A
Two approaches were used to validate the role of Akt signaling in mediating the enhancing effect of sorafenib CIP2A mediates effects of bortezomib in hepatocellular carcinoma K-F Chen et al on bortezomib-treated HCC cells. First, ectopic expression of CIP2A in a Sk-Hep1 (CIP2A-myc) cell line generated to stably express CIP2A constitutively was found to protect cells from apoptotic death induced by bortezomib, indicating that CIP2A has a key role in mediating the apoptotic effect of bortezomib in HCC cells (Figure 3a , right). In addition, over-expression of CIP2A up-regulates phospho-Akt, suggesting CIP2A might regulate Akt signals through the interaction with PP2A (Figure 3a , left). Furthermore, siRNA was used to knock down protein expression of CIP2A in resistant PLC5 cells. Down-regulation of CIP2A sensitizes the cells to bortezomib-induced apoptosis ( Figure 3b ). Next, silencing CIP2A restored the activity of bortezomib on PP2A phosphatase in PLC5 cells, suggesting CIP2A mediates the effect of bortezomib on PP2A and Akt (Figure 3c ). To confirm whether CIP2A-mediated bortezomib's effects through Akt signaling, we examined the effect of Akt inhibition in CIP2A-myc cells. Our data showed that silencing Akt1 by siRNA abrogated the protective effect of CIP2A on bortezomib-induced apoptosis (Figure 3d ). In addition, adding LY294002, a PI3K inhibitor (Figure 3e ), also increased bortezomib-induced apoptosis in CIP2A-myc cells, suggesting that CIP2A medicates bortezomib's effects through Akt signaling. It is of note that CIP2A depletion by siRNA did not induce apoptosis in PLC5, although P-Akt was down-regulated ( Figure 3f) . However, the combination of CIP2A depletion and bortezomib induced cell death significantly, suggesting that other targets of bortezomib, such as proteasome inhibition may have a role in mediating the combinational effect because Akt inhibition alone is not sufficient to induce apoptosis in PLC5 (Figure 3b) . Moreover, as Akt is activated in response to stimuli, such as growth factors, we examined the effect of epidermal growth factor on apoptosis and PAkt in bortezomib-treated cells. Our data showed that adding epidermal growth factor decreased the apoptotic cell death and up-regulated P-Akt in Sk-Hep1 cells (Figure 3g ), suggesting that epidermal growth factor protects cells from bortezomib-induced apoptosis by Akt signaling.
CIP2A inhibits Akt-associated PP2A activity According to a previous study, CIP2A may regulate phosphorylation of c-myc and subsequently affects its activity through the interaction with PP2A (Junttila et al., 2007) . However, it is unclear whether CIP2A influences the interaction between PP2A and its important substrate, Akt in cancer cells. Therefore, to investigate the role of CIP2A in the PP2A-Akt axis, we first knocked down CIP2A in Sk-Hep1 (CIP2A-myc). Inhibition of CIP2A by siRNA down-regulated P-Akt, whereas protein levels of PP2A complex did not alter (Figures 4a and d) . Next, we examined the Akt-related PP2A activity by co-immunoprecipitation of Akt in HCC cells. Over-expression of CIP2A decreased PP2A activity on Akt and inhibition of CIP2A by siRNA increased Akt-associated PP2A activity, suggesting that CIP2A has a role in regulating Akt-related PP2A activity (Figure 4b) . Furthermore, we found that the alterations of CIP2A did not affect the protein-protein interactions between Akt and PP2A, suggesting that CIP2A does not affect their binding affinity directly (Figure 4c ). It is of note that, although PP2A has been proposed to regulate P-Akt at both Ser473 and Thr308, our data showed that bortezomib down-regulated the phosphorylation of Akt at Ser473, but not Thr308 (Figure 2e ), which is consistent with our previous reports (Chen et al., 2008 (Chen et al., , 2009a . These data might suggest that the interaction between CIP2A and PP2A has more influence on the phosphorylation of Akt at Ser473. As CIP2A has just been discovered recently (Junttila et al., 2007) , many of its functions are still unclear. We need more work to elucidate the mechanism by which CIP2A regulates its interactive proteins, such as PP2A.
Bortezomib down-regulates transcription of CIP2A in HCC To examine the effects of bortezomib on CIP2A expression, we investigated whether bortezomib affects CIP2A transcription. As shown in Figure 5a , CIP2A mRNA was quantified using reverse transcriptase-PCR. It is of note that the treatment of Sk-Hep1 cells with bortezomib decreased mRNA levels of CIP2A in a timedependent manner. We hypothesized that if bortezomib indeed decreases CIP2A stability, then bortezomib should accelerate CIP2A elimination under conditions in which translation is blocked by a protein synthesis inhibitor, such as cycloheximide. Our data indicate that there is no discernible effect on the rate or extent of CIP2A1 down-regulation following the addition of bortezomib (Figure 5b ). In contrast, cycloheximide, either alone or in combination with bortezomib, had no effect on actin protein levels as cycloheximide by itself reduces CIP2A protein levels (Figure 5b ). The evidence of regulation shown in Figure 5 indicates that the effect of bortezomib on CIP2A occurs in pre-translation.
Effect of bortezomib on HCC xenograft tumor
To confirm whether the effect of bortezomib on CIP2A has potentially relevant clinical implications, we assessed the in vivo effect of bortezomib on HCC xenograft tumors. Tumor-bearing mice were treated with vehicle or bortezomib intraperitoneal. at the clinically relevant dose of 1.0 mg/kg twice a week for the duration of the study. All animals tolerated the treatments well without observable signs of toxicity and had stable body weights throughout the course of study. No gross pathologic abnormalities were noted at necropsy.
Our data indicated that bortezomib showed significant inhibitory effects on Huh-7 tumor growth (Figure 6a left) . In contrast, the same treatment of on PP2A activity (Figure 6d ) showed a significant increase in PP2A phosphatase activity (Po0.05) in Huh-7 tumors, but not in PLC5 tumors, indicating mediation of the effect by PP2A-dependent Akt inactivation in vivo. Further clinical investigation is warranted.
Discussion
The results of this study confirm our previous findings that suggested that bortezomib inhibits the Akt signaling pathway through up-regulation of PP2A activity in HCC cells (Chen et al., 2008) . Furthermore, our new results showed that a novel oncoprotein, CIP2A, is a major mediator of PP2A-dependnent Akt inactivation of bortezomib in HCC cells. These findings have several important implications. First, we found that the antitumor mechanism and drug-resistance of bortezomib in HCC cells depends on the CIP2A-PP2A-Akt signaling axis. There are several known bortezomib resistance mechanisms in cancer (McConkey and Zhu, 2008; Orlowski and Kuhn, 2008) . In this study, we have proposed a novel pathway that has potential implication for overcoming bortezomib resistance, particularly in solid tumors. Our and other studies has shown that sorafenib posse synergistic cytotoxicity when in-vitro combining bortezomib in treating various tumor cells, and such combination showed decreased P-Akt expression in co-treated cells (Yu et al., 2006; Chen et al., 2009b) . Furthermore, the combination of bortezomib with novel Akt inhibitors, such as perifosine, may be able to overcome the bortezomib resistance in HCC (Richardson et al., 2008) .
The second potentially important implication of this study is that CIP2A may act as a molecular determinant predictive of responsiveness to bortezomib. Our results clearly showed that bortezomib-resistant PLC cells consistently express CIP2A, whereas down-regulation of CIP2A by siRNA sensitizes the cells to bortezomibinduced apoptosis (Figure 3b) . Moreover, overexpression of ectopic CIP2A in bortezomib-sensitive cells (Sk-Hep1) protects the cells from bortezomib-induced cell deaths (Figure 3a) . These results imply that HCC cells with high CIP2A expression may be more resistant to bortezomib. In contrast, drugs that are able to significantly decrease CIP2A expression may show excellent sensitivity to HCC. Future work focusing on immunohistochemical study of in vivo HCC tumors and the correlation between CIP2A expressions and drugsensitivity in HCC patients is warranted to establish the clinical role of CIP2A as a predictive factor for treatment. It is interesting that the clinical role of CIP2A and its association with disease progression has recently been shown in breast cancer (Come et al., 2009) . Come et al. demonstrated that high CIP2A expression correlates with tumor grade and predicts a worse prognosis for breast cancer patients at 5-year followup (Come et al., 2009) .
It is well known that among PP2A substrates, CIP2A selectively targets the c-Myc-associated PP2A complex (Junttila et al., 2007) . CIP2A directly binds to c-Myc, protecting c-Myc serine 62 from dephosphorylation by PP2A. To date, PP2A is the only known target of CIP2A. However, other targets of CIP2A should be recognized in the future. Given the fact that most of CIP2A's functions are still unknown, it is certainly possible that CIP2A regulates apoptotic signals other than the PP2A/Akt pathway. In addition, adding to this known molecular interaction, our results clarify that CIP2A also influences the interaction between PP2A and another important substrate of it, in this case, p-Akt in HCC cells. However, the influence of CIP2A on p-Akt is neither by alteration of the protein levels of the PP2A-Akt complex (Figure 4a ), nor by affecting protein-binding affinity between Akt and PP2A ( Figure 4c) ; it is instead by decrease in PP2A activity toward p-Akt (Figure 4b) . Our results suggest that in addition to the inhibition of c-Myc-associated PP2A activity, CIP2A might exert its oncogenic property through the regulation of p-Akt and its downstream signaling, thereby increasing drug resistance in HCC cells.
The mechanisms by which bortezomib down-regulates CIP2A remain to be determined, our data showed that bortezomib is able to decrease CIP2A transcription, but does not affect the half-life of CIP2A protein degradation, suggesting that the effect of bortezomib on CIP2A occurs in pre-translation, and is possibly irrelevant to its proteasome inhibition. Bortezomib may affect the transcription of CIP2A through several possible mechanisms that include promotor regulation, epigenetic regulation, such as DNA methylation or micro-RNA production, and so on. Future work is needed to determine how bortezomib affects CIP2A transcription. It is of note that, it is well accepted that bortezomib failed to show clinical effects against most of solid tumor, including HCC, even though bortezomib has been approved in several types of hematological malignancies, such as multiple myeloma and mantel cell lymphoma (Orlowski and Kuhn, 2008) . This current study provides new evidence that CIP2A has a role in mediating bortezomib's effect on HCC and it may be a new therapeutic biomarker for patients with bortezomib treatment.
In addition, although we identified CIP2A-PP2A-Akt signaling regulation as important in HCC cells treated with bortezomib, we failed to demonstrate that knockdown of endogenous CIP2A in bortezomib-sensitive HCC cells (Sk-Hep1 cells, data not shown) also downregulates the endogenous p-Akt. One possible explanation is that in the wild-type Sk-Hep1 (bortezomib sensitive) HCC cells, the endogenous CIP2A and p-Akt protein levels may not be high enough for the down-regulation effect by siRNA to be observed. Aside from the pathway we proposed, there might be other off-target effects of bortezomib-induced cancer cell death. In this regard, Nikiforov et al. (2007) revealed that c-Myc is required for the up-regulation of NOXA in bortezomib-mediated proteasome inhibition and cell death in melanoma cells. In addition, they also demonstrated that enhancement of the intrinsic surplus of c-Myc could further sensitize bortezomibinduced melanoma cell death (Nikiforov et al., 2007) .
It is interesting that CIP2A has been shown to upregulate c-Myc expression in breast cancer cells (Come et al., 2009) , whereas CIP2A can be up-regulated by c-Myc in as a part of a positive feedback loop (Junttila et al., 2007; Khanna et al., 2009) . In this regard, we found that bortezomib did not alter c-Myc expression significantly among bortezomib-sensitive or -resistant HCC cells (data not shown).
In summary, this study has identified a mechanism by which CIP2A regulates PP2A and p-Akt in bortezomibinduced apoptosis in HCC cells and defined the determinant role of CIP2A in bortezomib sensitivity to HCC cells. It has also provided a molecular framework that focuses on the interaction of the oncoprotein and phosphatase to favor anticancer responses. Future studies to define the clinical role of CIP2A in HCC and, as well as the machinery by which bortezomib affects CIP2A expression, may lead to the improvement of targeted therapy in HCC and further clarify bortezomib's differential drug selectivity in solid tumors and hematologic malignancies.
Materials and methods

Reagents and antibodies
Bortezomib (Velcade) was kindly provided by Millennium Pharmaceuticals (Cambridge, MA, USA). For in vitro studies, bortezomib at various concentrations was dissolved in DMSO and then added to cells in Dulbecco's modified Eagle's medium containing 5% fetal bovine serum. The final DMSO concentration was 0.1% after addition to medium. Okadaic acid and 1,9 di-deoxy-forskolin were purchased from Cayman Chemical (Ann Arbor, MI, USA). Antibodies for immunoblotting, such as anti-Akt1, -poly (ADP-ribose) polymerase and -PP2A-C, were purchased from Santa Cruz Biotechnology (San Diego, CA, USA). Other antibodies such, as anti-caspase-3 and -P-Akt (Ser473 & Thr308), were from Cell Signaling (Danvers, MA, USA).
Cell culture and western blot analysis
The Sk-Hep1, PLC/PRF/5 (PLC5) and Hep3B cell lines were obtained from American Type Culture Collection (Manassas, VA, USA). The Huh-7 HCC cell line was obtained from the Health Science Research Resources Bank (Osaka, Japan; JCRB0403). Cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 units/ml, penicillin G, 100 mg/ml streptomycin sulfate and 25 mg/ml amphotericin B in a 37 1C humidified incubator and an atmosphere of 5% CO 2 in air. Lysates of HCC cells treated with drugs at the indicated concentrations for various periods of time were prepared for immunoblotting of caspase-3, poly (ADP-ribose) polymerase, P-Akt, Akt and so on. Western blot analysis was performed as previously described (Chen et al., 2008) .
Apoptosis analysis
Drug-induced apoptotic cell death was assessed by western blot analysis of activated caspases and cleaved poly (ADPribose) polymerase as described previously, and the number of apoptotic cells was assessed by flowcytometry (the number of cells in different stages of the cell cycle, as well as apoptotic (sub-G 1 ) cells) as described previously (Chen et al., 2008) .
Gene knockdown using siRNA Smartpool siRNA reagents, including control (D-001810-10), PP2A-C (L-003598-01) and CIP2A (L-014135-01) were all purchased from Dharmacon (Chicago, IL, USA). The procedure has been described previously (Chen et al., 2008) . Briefly, cells were transfected with siRNA (final concentration, 100 nM) in six-well plates using the Dharma-FECT4 transfection reagent (Dharmacon) according to the manufacturer's instructions. After 48 h, the medium was replaced and the HCC cells were incubated with bortezomib, harvested and separated for western blot analysis and for apoptosis analysis by flow cytometry as described previously (Chen et al., 2008) .
Sk-Hep1 with constitutive active CIP2A CIP2A cDNA (KIAA1524) was purchased from Origene (RC219918; Rockville, MD, USA). Briefly, following transfection, cells were incubated in the presence of G418 (0.78 mg/ml). After 8 weeks of selection, surviving colonies, that is, those arising from stably transfected cells, were selected and individually amplified. Sk-Hep1 cells with stable expression of CIP2A-myc were then treated with bortezomib, harvested and processed for western blot analysis as described previously.
Co-immunoprecipitation assay
Cells were harvested and lyzed on ice for 30 min in lysis buffer (50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 0.5% Nonidet P-40, 50 mM NaF, 1 mM Na 3 VO 4 , 5 mM sodium pyrophosphate and a protease inhibitor tablet). The cell lysates were centrifuged at 14 000 g for 15 min, and the supernatants were recovered. Supernatants containing equal amounts of proteins were incubated with 2.5 mg of primary antibodies overnight at 4 1C. The immunoprecipitates were harvested using protein G PLUS-agarose beads (Santa Cruz Biotechnology) that were washed once with regular washing buffer (50 mM Tris-HCl, 100 mM NaCl, 1 mM EDTA and 0.5% Nonidet P-40), twice with high-salt washing buffer (50 mM Tris-HCl, 500 mM NaCl, 1 mM EDTA and 0.5% Nonidet P-40) and finally with regular washing buffer. Immunoprecipitates were then eluted by boiling the beads for 5 min in SDS-PAGE sample buffer and characterized by western blotting with appropriate antibodies.
PP2A phosphatase activity
The protein phosphatase activity in total cellular lysate was determined by measuring the generation of free phosphate from threonine phosphopeptide using the malachite greenphosphate complex assay as described by the manufacturer (Upstate Biotechnology, Lake Placid, NY, USA). Cell lysates were prepared in a low-detergent lysis buffer (1% Nonidet P-40, 10 mM HEPES, 150 mM NaCl, 10% glycerol, 1 mM PMSF, 5 mM benzamidine, and 10 g/ml leupeptin). The phosphatase assay was performed in a PP2A-specific reaction buffer (Upstate) containing 750 mM phosphopeptide substrate. After 10 min of incubation at 30 1C, the malachite dye was added, and free phosphate was measured by optical density at 650 nm. To avoid variability due to differences in the amounts of immunoprecipitated protein between samples, the phosphatase activities were normalized to the amount of PP2A immunoprecipitated, as detected and quantified by immunoblot analysis for each treatment group.
Xenograft tumor growth
Male NCr athymic nude mice (5-7 weeks of age) were obtained from the National Laboratory Animal Center (Taipei, Taiwan). The mice were housed in groups and maintained under standard laboratory conditions on a 12-h light-dark cycle. They were given access to sterilized food and water ad libitum. All experimental procedures using these mice were performed in accordance with protocols approved by the Institutional Laboratory Animal Care and Use Committee of National Taiwan University. Each mouse was inoculated subcutaneous. in the dorsal flank with 1 Â 10 6 HCC cells suspended in 0.1 ml of serum-free medium containing 50% Matrigel (BD Biosciences, Bedford, MA, USA). When tumors reached 200-300 mm 3 , mice received an intra-peritoneal injection of bortezomib (1 mg per kg body weight) twice weekly. Controls received vehicle.
Statistical analysis
Tumor growth data points are reported as mean tumor volume±s.e. Comparisons of mean values were performed using the independent samples Student's t-test in SPSS for Windows 11.5 software (SPSS, Inc., Chicago, IL, USA).
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